Quanterix Corporation (NASDAQ:QTRX) Given Average Rating of "Hold" by Brokerages

Key Points

• Quanterix Corporation (NASDAQ:QTRX) has received an average rating of "Hold" from six research firms, with one sell rating, four hold ratings, and one buy rating, alongside a target price of $11.75.
• Recent institutional trading shows significant activity, with Peddock Capital Advisors increasing its stake by 196% and other firms like Trium Capital and Balyasny Asset Management also expanding their positions.
• Quanterix reported a quarterly loss of ($0.47) earnings per share, missing analyst estimates, while the company's stock is currently down 5.1% at a price of $5.75.

Quanterix Corporation (NASDAQ:QTRX - Get Free Report) has been given an average rating of "Hold" by the six research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $11.75.

QTRX has been the subject of a number of recent analyst reports. Canaccord Genuity Group reissued a "hold" rating and issued a $5.00 price objective (down previously from $12.00) on shares of Quanterix in a research report on Monday, August 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Quanterix in a research report on Wednesday, October 8th.

Institutional Trading of Quanterix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Peddock Capital Advisors LLC lifted its position in Quanterix by 196.0% during the 3rd quarter. Peddock Capital Advisors LLC now owns 52,105 shares of the company's stock worth $283,000 after acquiring an additional 34,503 shares during the period. Trium Capital LLP increased its stake in shares of Quanterix by 17.4% in the 3rd quarter. Trium Capital LLP now owns 688,597 shares of the company's stock valued at $3,739,000 after purchasing an additional 102,172 shares in the last quarter. State of Wyoming increased its stake in shares of Quanterix by 105.3% in the 2nd quarter. State of Wyoming now owns 14,814 shares of the company's stock valued at $99,000 after purchasing an additional 7,599 shares in the last quarter. Brevan Howard Capital Management LP purchased a new position in shares of Quanterix in the 2nd quarter valued at about $96,000. Finally, Balyasny Asset Management L.P. increased its stake in Quanterix by 1,625.2% during the 2nd quarter. Balyasny Asset Management L.P. now owns 767,801 shares of the company's stock worth $5,106,000 after buying an additional 723,295 shares in the last quarter. Institutional investors and hedge funds own 86.48% of the company's stock.

Quanterix Stock Down 5.1%

QTRX opened at $5.75 on Thursday. The stock's fifty day moving average is $5.18 and its two-hundred day moving average is $5.46. The company has a market capitalization of $267.20 million, a P/E ratio of -3.16 and a beta of 1.07. Quanterix has a 52 week low of $4.05 and a 52 week high of $15.67.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.06). Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. The company had revenue of $24.48 million during the quarter, compared to analysts' expectations of $29.73 million. Quanterix has set its FY 2025 guidance at EPS. Equities analysts anticipate that Quanterix will post -0.98 earnings per share for the current year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.